


## Tenuazonic acid

Cat. No.:	HY-N6715
CAS No.:	610-88-8
Molecular Formula:	C <sub>10</sub> H <sub>15</sub> NO <sub>3</sub>
Molecular Weight:	197.23
Target:	Influenza Virus; Bacterial; Enterovirus; Photosystem II
Pathway:	Anti-infection; Metabolic Enzyme/Protease
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (253.51 mM; Need ultrasonic)																									
	Preparing Stock Solutions	<table border="1"> <thead> <tr> <th>Solvent Concentration</th> <th>Mass</th> <th>1 mg</th> <th>5 mg</th> <th>10 mg</th> </tr> </thead> <tbody> <tr> <td>1 mM</td> <td></td> <td>5.0701 mL</td> <td>25.3506 mL</td> <td>50.7012 mL</td> </tr> <tr> <td>5 mM</td> <td></td> <td>1.0140 mL</td> <td>5.0701 mL</td> <td>10.1402 mL</td> </tr> <tr> <td>10 mM</td> <td></td> <td>0.5070 mL</td> <td>2.5351 mL</td> <td>5.0701 mL</td> </tr> </tbody> </table>	Solvent Concentration	Mass	1 mg	5 mg	10 mg	1 mM		5.0701 mL	25.3506 mL	50.7012 mL	5 mM		1.0140 mL	5.0701 mL	10.1402 mL	10 mM		0.5070 mL	2.5351 mL	5.0701 mL				
		Solvent Concentration	Mass	1 mg	5 mg	10 mg																				
		1 mM		5.0701 mL	25.3506 mL	50.7012 mL																				
		5 mM		1.0140 mL	5.0701 mL	10.1402 mL																				
10 mM		0.5070 mL	2.5351 mL	5.0701 mL																						
Please refer to the solubility information to select the appropriate solvent.																										
In Vivo	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 1.25 mg/mL (6.34 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline) Solubility: ≥ 1.25 mg/mL (6.34 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 1.25 mg/mL (6.34 mM); Clear solution</li> </ol>																									

### BIOLOGICAL ACTIVITY

Description	Tenuazonic acid is a nonhost-selective mycotoxin belonging to the tetramic acids family. Tenuazonic acid inhibits protein biosynthesis on ribosomes by suppressing the release of new protein. Tenuazonic acid is acutely toxic, and oral LD <sub>50</sub> is set between 81-186 mg/kg in rats and mice. Tenuazonic acid blocks electron transport beyond the primary quinone receptor (QA) by interacting with the D1 protein and is a <i>photosystem II (PSII)</i> inhibitor. In addition, Tenuazonic acid has antiviral effects on measles virus, enterovirus, respiratory virus and so on. Tenuazonic acid has an inhibitory effect on skin cancer <sup>[1][2][3][4][5][6][7]</sup> .
IC <sub>50</sub> & Target	ROS <sup>[4]</sup>

<b>In Vitro</b>	Tenuazonic acid (25 µg/ml; 24 h) regulates immune function through ROS production in leukocytes <sup>[4]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.																
<b>In Vivo</b>	<p>Tenuazonic acid (238-475 µg/kg; Oral administration/Intraperitoneal injection; 8 weeks) induces mycotoxicity in immunosuppressed mice<sup>[4]</sup>.</p> <p>Tenuazonic acid (125-500 µg; Topical application; Single dose) inhibits skin tumor in mice<sup>[5]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Cort-S (Hydrocortisone) (HY-N0583) treated swiss mice aged 3 months<sup>[4]</sup></td> </tr> <tr> <td>Dosage:</td> <td>238 µg/kg; 475 µg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection (i.p.); Oral administration (p.o.); 8 weeks</td> </tr> <tr> <td>Result:</td> <td>Caused hair loss and fatigue behavior in mice. Caused a notable decrease in feed intake and weight over the dosing weeks. Caused cysts and tumours in mice. Elevated malondialdehyde, reduced catalase and superoxide dismutase production, along with abnormal levels of aspartate aminotransferase and alanine transaminase.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>12-O-tetradecanoyl phorbol 13-acetate treated female Swiss albino mice (15 g)<sup>[5]</sup></td> </tr> <tr> <td>Dosage:</td> <td>125, 250 and 500 µg</td> </tr> <tr> <td>Administration:</td> <td>Topical application; Single dose</td> </tr> <tr> <td>Result:</td> <td>Inhibited the ornithine decarboxylase (ODC) induction. Significantly decreased the cumulative number of tumors, reduced the percentage of tumor bearing animals and the rate of tumor growth. Did not have much effect on the average body weight of the mice.</td> </tr> </table>	Animal Model:	Cort-S (Hydrocortisone) (HY-N0583) treated swiss mice aged 3 months <sup>[4]</sup>	Dosage:	238 µg/kg; 475 µg/kg	Administration:	Intraperitoneal injection (i.p.); Oral administration (p.o.); 8 weeks	Result:	Caused hair loss and fatigue behavior in mice. Caused a notable decrease in feed intake and weight over the dosing weeks. Caused cysts and tumours in mice. Elevated malondialdehyde, reduced catalase and superoxide dismutase production, along with abnormal levels of aspartate aminotransferase and alanine transaminase.	Animal Model:	12-O-tetradecanoyl phorbol 13-acetate treated female Swiss albino mice (15 g) <sup>[5]</sup>	Dosage:	125, 250 and 500 µg	Administration:	Topical application; Single dose	Result:	Inhibited the ornithine decarboxylase (ODC) induction. Significantly decreased the cumulative number of tumors, reduced the percentage of tumor bearing animals and the rate of tumor growth. Did not have much effect on the average body weight of the mice.
Animal Model:	Cort-S (Hydrocortisone) (HY-N0583) treated swiss mice aged 3 months <sup>[4]</sup>																
Dosage:	238 µg/kg; 475 µg/kg																
Administration:	Intraperitoneal injection (i.p.); Oral administration (p.o.); 8 weeks																
Result:	Caused hair loss and fatigue behavior in mice. Caused a notable decrease in feed intake and weight over the dosing weeks. Caused cysts and tumours in mice. Elevated malondialdehyde, reduced catalase and superoxide dismutase production, along with abnormal levels of aspartate aminotransferase and alanine transaminase.																
Animal Model:	12-O-tetradecanoyl phorbol 13-acetate treated female Swiss albino mice (15 g) <sup>[5]</sup>																
Dosage:	125, 250 and 500 µg																
Administration:	Topical application; Single dose																
Result:	Inhibited the ornithine decarboxylase (ODC) induction. Significantly decreased the cumulative number of tumors, reduced the percentage of tumor bearing animals and the rate of tumor growth. Did not have much effect on the average body weight of the mice.																

## REFERENCES

- [1]. MILLER FA, et al. ANTIVIRAL ACTIVITY OF TENUAZONIC ACID. *Nature*. 1963 Dec 28;200:1338-9.
- [2]. Kumari A, et al. Tenuazonic acid-induced mycotoxicosis in an immunosuppressed mouse model and its prophylaxis with cinnamaldehyde. *Chemosphere*. 2024 Sep;363:142812.
- [3]. Antony M, et al. Inhibition of mouse skin tumor promotion by tenuazonic acid. *Cancer Lett*. 1991 Dec 9;61(1):21-5.
- [4]. Yun CS, Motoyama T, Osada H. Biosynthesis of the mycotoxin tenuazonic acid by a fungal NRPS-PKS hybrid enzyme. *Nat Commun*. 2015 Oct 27;6:8758.
- [5]. Gil-Serna J., et al. Encyclopedia of Food Microbiology. MYCOTOXINS | Toxicology. 2014 887–892.
- [6]. Zhou B, et al. An evaluation of tenuazonic acid, a potential biobased herbicide in cotton. *Pest Manag Sci*. 2019 Mar 7.
- [7]. Chen S, et al. Recent advances in tenuazonic acid as a potential herbicide. *Pestic Biochem Physiol*. 2017 Nov;143:252-257.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA